fosamprenavir has been researched along with tacrolimus in 2 studies
| Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (tacrolimus) | Trials (tacrolimus) | Recent Studies (post-2010) (tacrolimus) |
|---|---|---|---|---|---|
| 174 | 55 | 37 | 17,757 | 2,319 | 6,661 |
| Protein | Taxonomy | fosamprenavir (IC50) | tacrolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.18 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.58 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.385 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0021 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.2547 | |
| Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform | Homo sapiens (human) | 0.0148 | |
| Splicing factor 3B subunit 3 | Homo sapiens (human) | 0.0123 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.3 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Adani, GL; Bresadola, V; Furlanut, M; Londero, A; Pavan, F; Pea, F; Tavio, M; Viale, P | 1 |
1 review(s) available for fosamprenavir and tacrolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for fosamprenavir and tacrolimus
| Article | Year |
|---|---|
Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.
Topics: Adult; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Nelfinavir; Organophosphates; Sulfonamides; Tacrolimus | 2008 |